Development of novel HCV treatment using oral vaccine

2016 Fiscal Year Final Research Report

• Project/Area Number: 26461503
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Infectious disease medicine
• Research Institution: Kobe University
• Principal Investigator: SHIRAKAWA TOSHIRO 神戸大学, 科学技術イノベーション研究科, 教授 (70335446)
• Co-Investigator(Renkei-kenkyūsha): KATAYAMA Takane 東京大学, 大学院生命科学研究科, 教授 (70346104)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 経口ワクチン / 慢性C型肝炎 / ビフィズス菌

Outline of Final Research Achievements

Currently, there are about 170 million HCV (hepatitis C virus) carriers worldwide. Although the treatment outcomes for chronic HCV infection have been improved with interferon and antiviral drugs, the curative rate is still not satisfactory. Recently, we have generated a novel oral HCV vaccine displaying HCV-NS3 protein on the cell surface of bifidobacteria and confirmed that it could induce the HCV-specific cellular immunity in a mouse experimental model. In this study, we have developed novel combinational oral vaccine therapy for HCV infection and confirmed its synergistic effect with interferon using a mouse syngeneic tumor model expressing NS3 protein.

Free Research Field

遺伝子治療学